Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

PartnershipopakalimPositive

AI Analysis

Summary

Biohaven and SK Biopharmaceuticals entered into a strategic global licensing agreement for the Kv7 ion channel platform with upfront and milestone payments up to $795 million, plus tiered royalties ranging from mid-teens to low twenties on U.S. net sales of opakalim, an epilepsy candidate.

Outcome Details

Strategic global licensing agreement for Kv7 ion channel platform

Importance:7/10

Sentiment:

0.75

licensingpartnershipepilepsyKv7 ion channelopakalimmilestone paymentsroyalties

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Biotech on August 26, 2026 6:36 AM

Read Original